6769 MESA RIDGE RD., SAN DIEGO, CA
Bylaws Amendment Approved; Role of Chairman Clarified at Inovio Pharmaceuticals
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Announces Pricing of $17.5 Million Public Offering
Other Events
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Inovio Pharmaceuticals Extends Series A Warrants Expiration to March 2026
FDA Accepts for Review BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)
Announces Pricing of $25 Million Public Offering
Q1
FY 2025
Q3
Q2
FY 2024
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership